Lexaria Bioscience (LEXX) Gross Profit (2017 - 2026)
Lexaria Bioscience (LEXX) posted Gross Profit of $20000.0 for Q1 2026, down 88.51% sequentially from $174000.0 in Q3 2025, and down 88.51% YoY from $174000.0 in Q1 2025.
Lexaria Bioscience (LEXX) Gross Profit (2017 - 2026) Analysis & Trends
Lexaria Bioscience has reported Gross Profit for 10 years, with the latest figure at $20000.0 in Q1 2026.
- Quarterly Gross Profit fell 88.51% year-over-year to $20000.0 in Q1 2026, while the trailing twelve-month figure through May 2026 was $194000.0 (down 68.36% YoY) and the FY2025 annual result came in at $703203.0, up 53.05% from the prior year.
- Gross Profit declined to $20000.0 in Q1 2026 per LEXX's latest filing, from $174000.0 in the prior quarter.
- Over five years, Gross Profit peaked at $181203.0 in Q4 2024 and troughed at $20000.0 in Q1 2026.
- A 5-year average of $103125.1 and a median of $84000.0 in 2024 frame the typical range for Gross Profit.
- The sharpest annual moves came in 2022 and 2026: Gross Profit jumped 886.04% in 2022, then plunged 88.51% in 2026.
- Over 5 years, Gross Profit stood at $81940.0 in 2022, then jumped by 78.74% to $146456.0 in 2023, then advanced by 23.73% to $181203.0 in 2024, then retreated by 3.98% to $174000.0 in 2025, then slumped by 88.51% to $20000.0 in 2026.
- According to Business Quant data, Gross Profit over the past three periods registered $20000.0, $174000.0, and $174000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 20,000.00 |
| Feb 28, 2026 | 20,000.00 |
| Aug 31, 2025 | 174,000.00 |
| Aug 31, 2025 | 174,000.00 |
| May 31, 2025 | 174,000.00 |
| May 31, 2025 | 174,000.00 |
| Feb 28, 2025 | 174,000.00 |
| Feb 28, 2025 | 174,000.00 |
| Nov 30, 2024 | 181,203.00 |
| Nov 30, 2024 | 181,203.00 |
| Aug 31, 2024 | 84,000.00 |
| Aug 31, 2024 | 84,000.00 |
| May 31, 2024 | 84,000.00 |
| May 31, 2024 | 84,000.00 |
| Feb 29, 2024 | 145,000.00 |
| Feb 29, 2024 | 145,000.00 |
| Nov 30, 2023 | 146,456.00 |
| Nov 30, 2023 | 146,456.00 |
| Aug 31, 2023 | 30,741.00 |
| Aug 31, 2023 | 30,741.00 |